Eltrombopag

Phase 3UNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Immune Thrombocytopenic Purpura (ITP)

Conditions

Immune Thrombocytopenic Purpura (ITP)

Trial Timeline

Jul 1, 2016 → Sep 1, 2017

NCT ID

NCT02877212

About Eltrombopag

Eltrombopag is a phase 3 stage product being developed by Novartis for Immune Thrombocytopenic Purpura (ITP). The current trial status is unknown. This product is registered under clinical trial identifier NCT02877212. Target conditions include Immune Thrombocytopenic Purpura (ITP).

What happened to similar drugs?

7 of 20 similar drugs in Immune Thrombocytopenic Purpura (ITP) were approved

Approved (7) Terminated (2) Active (13)

✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved

✅IgPro10CSLApproved

✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved

✅Methylprednisolone + PrednisoloneBiogenApproved

✅Flebogamma 5% DIFGrifolsApproved

✅Asceniv™ADMA BiologicsApproved

✅BivigamADMA BiologicsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04837703	Pre-clinical	Active	—	—	Thrombocytopenia
NCT05286164	Phase 2	UNKNOWN	Apr 1, 2022	Apr 1, 2024	CART Treatment
NCT03988608	Phase 2	Completed	Dec 9, 2019	May 17, 2023	Aplastic Anemia
NCT03718533	Phase 2	Terminated	Dec 17, 2018	Nov 3, 2020	Poor Graft Function
NCT03664518	Phase 2	Completed	Dec 4, 2018	Sep 30, 2022	Thrombocytopenia Purpura
NCT03524612	Phase 2	Completed	Nov 2, 2018	Oct 3, 2022	Immune Thrombocytopenic Purpura (ITP)
NCT02877212	Phase 3	UNKNOWN	Jul 1, 2016	Sep 1, 2017	Immune Thrombocytopenic Purpura (ITP)
NCT02323178	Phase 1/2	Completed	Aug 7, 2014	Apr 1, 2021	CMML
NCT01703169	Phase 2	Completed	Nov 1, 2012	Jun 1, 2016	Severe Aplastic Anemia
NCT01715779	Pre-clinical	Completed	Aug 1, 2012	Jun 1, 2015	Hepatitis C
NCT01416311	Pre-clinical	Completed	Dec 21, 2010	Oct 16, 2020	Purpura, Thrombocytopaenic, Idiopathic

Competing Products

20 competing products in Immune Thrombocytopenic Purpura (ITP)

See all competitors

Product	Company	Stage	Hype Score
Pirtobrutinib + Placebo	Eli Lilly	Phase 1/2	39
Anti-(integrin beta-3) human monoclonal antibody	Rallybio	Phase 2	17
Satralizumab	Chugai Pharmaceutical	Phase 3	47
Placebo + Lusutrombopag	Shionogi	Phase 2	27
Lusutrombopag	Shionogi	Phase 2	27
Romiplostim	Kyowa Kirin	Phase 1/2	32
AMG 531	Kyowa Kirin	Phase 2/3	38
Romiplostim + Placebo	Kyowa Kirin	Phase 3	40
Romiplostim (AMG-531)	Kyowa Kirin	Phase 2	35
Romiplostim and danazol	Kyowa Kirin	Phase 2	31
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	29
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	29
Hetrombopag + Placebo	Jiangsu Hengrui Medicine	Phase 3	40
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	35
Herombopag	Jiangsu Hengrui Medicine	Phase 3	36
Zostavax®	Merck	Pre-clinical	18
Raltegravir + Atazanavir	Merck	Pre-clinical	26
Zostavax	Merck	Pre-clinical	26
MK-8723 + Matching Placebo	Merck	Phase 1	29